Display options
Cite
Siva S, Bressel M, Mai T, et al. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(10):1476-1485doi: 10.1001/jamaoncol.2021.2939.
Siva, S., Bressel, M., Mai, T., Le, H., Vinod, S., de Silva, H., Macdonald, S., Skala, M., Hardcastle, N., Rezo, A., Pryor, D., Gill, S., Higgs, B., Wagenfuehr, K., Montgomery, R., Awad, R., Chesson, B., Eade, T., Wong, W., Sasso, G., De Abreu Lourenco, R., Kron, T., Ball, D., Neeson, P. (2021). Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA oncology, 7(10), 1476-1485. https://doi.org/10.1001/jamaoncol.2021.2939
Siva, Shankar, et al. "Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial." JAMA oncology vol. 7,10 (2021): 1476-1485. doi: https://doi.org/10.1001/jamaoncol.2021.2939
Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. PMID: 34455431; PMCID: PMC8404145.
Copy Download .nbib Format: NLM
Share it on

JAMA Oncol. 2021 Oct 01;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939.

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.

JAMA oncology

Shankar Siva, Mathias Bressel, Tao Mai, Hien Le, Shalini Vinod, Harini de Silva, Sean Macdonald, Marketa Skala, Nicholas Hardcastle, Angela Rezo, David Pryor, Suki Gill, Braden Higgs, Kassandra Wagenfuehr, Rebecca Montgomery, Raef Awad, Brent Chesson, Thomas Eade, Wenchang Wong, Giuseppe Sasso, Richard De Abreu Lourenco, Tomas Kron, David Ball, Paul Neeson,

Affiliations

  1. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Victoria, Australia.
  2. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.
  3. Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Victoria, Australia.
  4. Radiation Oncology Centre, Princess Alexandra Hospital, Queensland, Australia.
  5. Department of Radiation Oncology, Royal Adelaide Hospital, South Australia, Australia.
  6. Cancer Therapy Centre, Liverpool Hospital, New South Wales, Australia.
  7. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  8. Royal Hobart Hospital, Tasmania, Australia.
  9. Department of Physical Sciences, Peter MacCallum Cancer Centre, Victoria, Australia.
  10. Canberra Hospital, Garran, Australian Capital Territory, Australia.
  11. Sir Charles Gairdner Hospital, Western Australia, Australia.
  12. Trans Tasman Radiation Oncology Group (TROG) Cancer Research, New South Wales, Australia.
  13. Department of Radiation Therapy, Peter MacCallum Cancer Centre, Victoria, Australia.
  14. Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  15. Department of Radiation Oncology, Prince of Wales Hospital, New South Wales, Australia.
  16. Radiation Oncology Department, Auckland City Hospital, New Zealand.
  17. Centre for Health Economics Research and Evaluation, University of Technology Sydney, New South Wales, Australia.

PMID: 34455431 PMCID: PMC8404145 DOI: 10.1001/jamaoncol.2021.2939

Abstract

IMPORTANCE: Evidence is lacking from randomized clinical trials to guide the optimal approach for stereotactic ablative body radiotherapy (SABR) in patients with pulmonary oligometastases.

OBJECTIVE: To assess whether single-fraction or multifraction SABR is more effective for the treatment of patients with pulmonary oligometastases.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, unblinded, phase 2 randomized clinical trial of 90 patients across 13 centers in Australia and New Zealand enrolled patients with 1 to 3 lung oligometastases less than or equal to 5 cm from any nonhematologic malignant tumors located away from the central airways, Eastern Cooperative Oncology Group performance status 0 or 1, and all primary and extrathoracic disease controlled with local therapy. Enrollment was from January 1, 2015, to December 31, 2018, with a minimum patient follow-up of 2 years.

INTERVENTIONS: Single fraction of 28 Gy (single-fraction arm) or 4 fractions of 12 Gy (multifraction arm) to each oligometastasis.

MAIN OUTCOMES AND MEASURES: The main outcome was grade 3 or higher treatment-related adverse events (AEs) occurring within 1 year of SABR. Secondary outcomes were freedom from local failure, overall survival, disease-free survival, and patient-reported outcomes (MD Anderson Symptom Inventory-Lung Cancer and EuroQol 5-dimension visual analog scale).

RESULTS: Ninety participants were randomized, of whom 87 were treated for 133 pulmonary oligometastases. The mean (SD) age was 66.6 [11.6] years; 58 (64%) were male. Median follow-up was 36.5 months (interquartile range, 24.8-43.9 months). The numbers of grade 3 or higher AEs related to treatment at 1 year were 2 (5%; 80% CI, 1%-13%) in the single-fraction arm and 1 (3%; 80% CI, 0%-10%) in the multifraction arm, with no significant difference observed between arms. One grade 5 AE occurred in the multifraction arm. No significant differences were found between the multifraction arm and single-fraction arm for freedom from local failure (hazard ratio [HR], 0.5; 95% CI, 0.2-1.3; P = .13), overall survival (HR, 1.5; 95% CI, 0.6-3.7; P = .44), or disease-free survival (HR, 1.0; 95% CI, 0.6-1.6; P > .99). There were no significant differences observed in patient-reported outcomes.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, neither arm demonstrated evidence of superior safety, efficacy, or symptom burden; however, single-fraction SABR is more efficient to deliver. Therefore, single-fraction SABR, as assessed by the most acceptable outcome profile from all end points, could be chosen to escalate to future studies.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01965223.

Publication Types